Management of Advanced Adult Soft Tissue Sarcoma

Bramwell, Vivien

doi:10.1080/13577140310001607266

Cited by 7 publications

(2 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison, in Europe, VAC therapy is substituted for a regimen consisting of ifosfamide, vincristine, and actinomycin D (IVA), which has produced similar treatment outcomes [4,5]. There is no standardized chemotherapy regimen for the adult patients, with some studies suggest using a combination of ifosfamide, doxorubicin, and vincristine, while others utilize pediatric regimens such as VAC [3,57]. When treating RMS, chemotherapy is typically administered in intervals over a 6-to 9-months period [4].…”

Section: Rms Treatmentmentioning

confidence: 99%

Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies

Zarrabi,

Perrin,

Kavoosi

et al. 2023

Cancers

View full text Add to dashboard Cite

Rhabdomyosarcoma is a rare cancer arising in skeletal muscle that typically impacts children and young adults. It is a worldwide challenge in child health as treatment outcomes for metastatic and recurrent disease still pose a major concern for both basic and clinical scientists. The treatment strategies for rhabdomyosarcoma include multi-agent chemotherapies after surgical resection with or without ionization radiotherapy. In this comprehensive review, we first provide a detailed clinical understanding of rhabdomyosarcoma including its classification and subtypes, diagnosis, and treatment strategies. Later, we focus on chemotherapy strategies for this childhood sarcoma and discuss the impact of three mechanisms that are involved in the chemotherapy response including apoptosis, macro-autophagy, and the unfolded protein response. Finally, we discuss in vivo mouse and zebrafish models and in vitro three-dimensional bioengineering models of rhabdomyosarcoma to screen future therapeutic approaches and promote muscle regeneration.

show abstract

Section: Rms Treatmentmentioning

confidence: 99%

Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies

Zarrabi,

Perrin,

Kavoosi

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…introduction More than half of patients treated for localized soft tissue sarcoma will experience relapse. Anthracycline-based chemotherapy remains the standard of care in the first-line setting [1], including topoisomerase II inhibitors doxorubicin and epirubicin that act by increasing DNA damage and promoting apoptosis [2]. Response rates are low and resistance to doxorubicin is common [3,4].…”

mentioning

confidence: 99%